CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Revenues	$ 111,299	$ 110,701	$ 118,192
Operating expenses:
Research and development	249,898	230,819	180,647
General and administrative	62,682	63,219	67,097
Total operating expenses	312,580	294,038	247,744
Loss from operations	(201,281)	(183,337)	(129,552)
Interest and other income, net	9,432	5,346	8,775
Loss before income taxes	(191,849)	(177,991)	(120,777)
Income tax expense	429	306	345
Net loss	(192,278)	(178,297)	(121,122)
Net loss attributable to non-controlling interest	0	(11)	(126)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders	$ (192,278)	$ (178,286)	$ (120,996)
Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.25)	$ (1.23)	$ (0.90)
Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (1.25)	$ (1.23)	$ (0.90)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	154,345	144,568	134,449
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	154,345	144,568	134,449